Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of Operating Expenses readings, the most recent being $3.0 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 21.93% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.0 million, a 19.34% decrease, with the full-year FY2025 number at $13.0 million, down 19.34% from a year prior.
  • Operating Expenses hit $3.0 million in Q4 2025 for CollPlant Biotechnologies, down from $3.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $4.7 million in Q4 2022 to a low of $3.0 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $3.8 million (2022), compared with a mean of $3.8 million.
  • The widest YoY moves for Operating Expenses: up 100.06% in 2021, down 99.84% in 2021.
  • CollPlant Biotechnologies' Operating Expenses stood at $3.6 million in 2021, then soared by 31.02% to $4.7 million in 2022, then decreased by 1.67% to $4.6 million in 2023, then dropped by 15.85% to $3.9 million in 2024, then fell by 21.93% to $3.0 million in 2025.
  • The last three reported values for Operating Expenses were $3.0 million (Q4 2025), $3.3 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.